post-COVID-19 Qi deficiency syndrome
Conditions
Interventions
Liuzijue Qigong group:Based on the treatment of qi deficiency syndrome in patients who have tested negative for COVID-19, interventions such as dietary guidance, psychological intervention, medication
control group:Based on the treatment of qi deficiency syndrome in patients who have tested negative for COVID-19, interventions such as dietary guidance, psychological intervention, medication instruc
Sponsors
Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) During the onset of COVID-19, the diagnosis criteria for confirmed cases of mild, moderate, and severe COVID-19 pneumonia in accordance with the "Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial Version 10)" were met. After treatment, the following conditions appeared: (a) Negative nucleic acid test for COVID-19; (b) Negative antigen test for COVID-19; (c) Negative viral isolation and culture for COVID-19. (2) Referring to the criteria for diagnosing qi deficiency syndrome in the "Guiding Principles for Clinical Research of New Drugs in China (Trial Version)," qi deficiency syndrome is characterized by: main symptoms of shortness of breath, fatigue, mental exhaustion, and weak pulse; and accompanying symptoms of spontaneous sweating, aversion to speaking, and pale tongue. Patients who meet the criteria of having 2 main symptoms and 1 accompanying symptom of qi deficiency syndrome. (3) Age between 18 and 60 years old. (4) Stable vital signs. (5) Willingly participate in this trial and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with severe and critical cases of COVID-19. (2) Patients with other respiratory system diseases such as tuberculosis, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and lung cancer. (3) Patients with certain infectious diseases or acute contagious diseases, such as acute hepatitis. (4) Patients with bleeding tendencies, such as hemophilia or traumatic bleeding. (5) Patients with organ failure, such as respiratory failure or heart failure. (6) Patients with mental, intellectual, or cognitive abnormalities who are unable to cooperate. (7) Patients with severe cardiovascular, cerebrovascular, renal, hepatic, neurological diseases, or malignant tumors. (8) Patients with musculoskeletal disorders or functional disabilities who are unable to complete the required physical activities. (9) Patients with contraindications for rehabilitation treatment. (10) Pregnant women. (11) Participants who have participated in other clinical trials within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The SF-36 scale;St george's respiratory questionaire; | — |
Secondary
| Measure | Time frame |
|---|---|
| Self-rating depression scale;Self-Rating Anxiety Scale;Pittsburgh sleep quality index; | — |
Countries
China
Contacts
Public ContactDingnan Wang
Beijing University of Chinese Medicine
Outcome results
None listed